(Bloomberg) -- Hedge-fund manager Kyle Bass has a plan that could cut the high cost of prescription drugs in the U.S. -- and make himself a lot of money. The strategy: Take short positions in a number of pharmaceutical companies while also trying to overturn their drug patents in court. Joining hosts Tracy Alloway and Joe Weisenthal to discuss Bass's unusual tactic is Guan Yang, an occasional Bloomberg View contributor who has researched the odd intersection of Wall Street and patent law.